A single dose of eculizumab terminated life‐threatening haemolysis in idiopathic IgM‐mediated warm autoimmune haemolytic anaemia: A case report

2022 ◽  
Author(s):  
Mamta Garg ◽  
Siddharth Agarwal ◽  
Mohammed Altohami
Keyword(s):  
Single Dose ◽  
Case Report ◽  
Haemolytic Anaemia ◽  
Autoimmune Haemolytic Anaemia ◽  
Life Threatening

Myasthenia gravis with thymoma and autoimmune haemolytic anaemia. A case report

2003 ◽  
Vol 24 (1) ◽  
pp. 34-36 ◽  
Author(s):  
N. Tuncer Elmaci ◽  
S. Ratip ◽  
D. ?nce-G�nal ◽  
T. Tanrida?
Keyword(s):  
Case Report ◽  
Myasthenia Gravis ◽  
Haemolytic Anaemia ◽  
Autoimmune Haemolytic Anaemia

scholarly journals Pembrolizumab-induced autoimmune haemolytic anaemia and cholangitis

2019 ◽  
Vol 12 (12) ◽  
pp. e232505 ◽  
Author(s):  
Harriet Williams ◽  
Robin Aitchison
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Haemolytic Anaemia ◽  
De Novo ◽  
Checkpoint Inhibitors ◽  
Autoimmune Haemolytic Anaemia ◽  
Dermatological Disease ◽  
Wide Range ◽  
Life Threatening ◽  
Life Threatening Complication

Increasing numbers of patients are now offered immunotherapy as part of their cancer treatment. These treatments, while often very effective, have a wide range of adverse effects that are distinct from those of traditional chemotherapy regimens. Thyroid disease, dermatological disease, colitis and pneumonitis are some of the most commonly reported immune side effects. We present a case of life-threatening de novo autoimmune haemolytic anaemia (AIHA) complicated by immune cholangitis induced by pembrolizumab. An 81-year-old woman with metastatic melanoma completed a two-year course of pembrolizumab in August 2018 and six weeks later presented to hospital with jaundice. Admission haemoglobin (Hb) was 91 g/L, rapidly decreasing to 31 g/L, at which point she required admission to the intensive care unit. AIHA is a rare but potentially life-threatening complication of checkpoint inhibitors and should be considered in patients presenting with anaemia during or after immunotherapy treatment.

Case report: A patient with primary biliary cirrhosis and autoimmune haemolytic anaemia

1996 ◽  
Vol 11 (5) ◽  
pp. 439-442 ◽  
Author(s):  
ERIC M YOSHIDA ◽  
STEPHEN H NANTEL ◽  
DAVID A OWEN ◽  
PAUL F GALBRAITH ◽  
BAKUL I DALAL ◽  
...  
Keyword(s):  
Case Report ◽  
Primary Biliary Cirrhosis ◽  
Haemolytic Anaemia ◽  
Autoimmune Haemolytic Anaemia ◽  
Biliary Cirrhosis

An elderly man presented with autoimmune haemolytic anaemia- a consequence of severe corona virus disease 19 (COVID-19)

2021 ◽  
pp. 57-59
Author(s):  
Md Nazmul Hasan ◽  
Chowdhury Adnan Sami ◽  
Md Rasul Amin ◽  
Abed Hussain Khan ◽  
Sunil Kumar Biswas
Keyword(s):  
Case Report ◽  
Connective Tissue ◽  
Connective Tissue Disease ◽  
Haemolytic Anaemia ◽  
Lymphoproliferative Disorder ◽  
Virus Disease ◽  
Autoimmune Haemolytic Anaemia ◽  
Corona Virus ◽  
Increased Risk

Autoimmune hemolytic anaemia (AIHA) can be caused by many diseases like connective tissue disease, lymphoproliferative disorder, certain infections and various medications. The coronavirus disease 19(COVID-19) can cause an increased risk of thrombosis. But, the association of AIHA with COVID-19 is not well understood. Here, in this case report a 45-year-old man who presented with fever, cough, anaemia and splenomegaly. On further investigation, he was confirmed as severe COVID-19 case with AIHA. Subsequently he was managed with prednisolone with good results. BSMMU J 2021; 14 (COVID -19 Supplement): 57-59

Sign in / Sign up

Export Citation Format

Share Document